2017-06-292026-03-272017-06-292010Tomás Martínez Ibarra1091-426910.1002/da.20639   https://doi.org/10.1002/da.20639https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851829/https://repositorio.inprf.gob.mx/handle/123456789/5334SAD and numerous outcomes (age-of-onset, persistence, severity, comorbidity, treatment) were examined. Additional analyses examined associations with number of performance fears Versus number of interactional fears. Results: Lifetime social fears are quite common in both developed (15.9%) and developing (14.3%) countries, but lifetime SAD is much more common in the former (6.1%) than latter (2.1%) countries. Among those with SAD, persistence, severity, comorbidity, and treatment have dose response relationships with number of social fears, with no clear nonlinearity in relationships that would support a distinction between generalized and non-generalized SAD. The distinction between performance fears and interactional fears is generally not important in predicting these same outcomes. Conclusion: No evidence is found to support subtyping SAD on the basis of either number of social fears or number of performance fears versus number of interactional fears. Depression and Anxiety 27:390-403, 2010. (C) 2009 Wiley-Liss, Inc.engacceso cerradoarticle4Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz390-403Hoboken27Social anxiety disorderSocial phobiaEpidemiologySubtypeTrastorno de ansiedad socialFobia socialEpidemiologíaSubtipoMental health surveysAvoidant personality disorderPhobia subtypesOrganizationNational Comorbidity SurveyDiagnosisEfficacyVersionFearsCIDI